Gilead reports data for GS 9190, GS 9256 combinations

Gilead Sciences Inc. (NASDAQ:GILD) reported data from the Phase IIa Study 196-0112 trial evaluating GS 9190 and GS 9256 in 45 treatment-naive HCV patients with HCV genotype 1 infection. The company said dual therapy of twice-daily GS 9190 and GS 9256 produced a median maximal decline from baseline in HCV RNA of 4.1 log10 IU/mL at day 28. Triple therapy with GS 9190, GS 9256 and Copegus ribavirin led to a median maximal decline from baseline in HCV RNA of 5.1 log10 IU/mL during the 28-day treatment period. Elevations in bilirubin were also observed in all treatment arms. ...